The human and mouse met protooncogenes encode proteins that have the characteristics of growth factor receptors. Thus, the 1408 amino acid human met protein (Park et al., 1987) can be divided into several putative domains, including an intracellular protein tyrosine kinase (PTK) domain, a transmembrane domain and a 926 amino acid extracellular domain that possesses a cysteine-rich region. An activa-ed form of the met gene that is present in the chemicallytransformed human cell line (MNNG-HOS) was originally detected by its ability to transform NIH3T3 mouse fibroblasts in DNA transfection experiments (Cooper et al., 1984a, b). Activation of met involves a chromosomal rearrangement in which the regions of the met gene encoding the transmembrane and extracellular domain are replaced by a portion of an unrelated gene that has been designated tpr (Park et al., 1986a; Tempest et al., 1986a). The chimaeric gene is transcribed to produce a 5.0 kb hybrid mRNA that is in turn translated to form a fusion protein. DNA sequence analysis of cDNA clones prepared from transcripts of the activated human met gene reveal that all of the met PTK domain is retained in the product of the activated gene and that the region of the fusion protein encoded by the tpr gene exhibits weak homology to laminin Bi (Chan et al., 1987) . Alterations of met were also observed in lines of spontaneously transformed mouse fibroblasts where a modest (4-8 fold) amplification of the protooncogene is accompanied by dramatic (50-100 fold) increase in the level of an 8.5 kb met transcript (Cooper et al., 1986) .
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Northern analysis of mRNAs from a series of human cell lines has revealed a complex pattern of transcription of the met protooncogene (Park et al., 1986) . Many cell lines, including a human fibroblast cell line, contain a single 9.0 kb mRNA species. Other cell lines such as the CaLu-I lung tumour line contain both 9.0 kb and 7.0 kb mRNAs while the most complex pattern of transcription of the normal met gene is present in MNNG-HOS cells and in the parent HOS cell line, which both contain 9.0 kb, 7.0 kb and 6.0 kb mRNA species. Most B-cell and T-cell tumour lines do not contain detectable levels of met transcripts.
Antibodies raised against synthetic peptides corresponding to the carboxyl terminus of the predicted met gene product have been used to detect proteins encoded by the activated and normal met genes (Park et al., 1986b; Tempest et al., 1986b Tempest et al. (1986b) , although in this particular study of low level of phosphorylation of a 165 kD protein, which probably corresponds to the 160 kD protein detected by Park et al. (1986b) , was also observed.
As a first step in determining whether alterations in met can be implicated in the induction of human tumours we have used antipeptide antibodies to examine met protein kinase activity in a series of human tumour cell lines. In addition, to help understand the large quantitative and qualitative variations in met kinase activity observed in these experiments, we have used SDS-polyacrylamide gel electrophoresis to examine the structure of the mature met protein.
Materials and methods
Cell lines Human MNNG-HOS and HOS cells were obtained from Dr J. Rhim, A431 and C-4I human cervical carcinoma cells, HL60 human promyelocytic leukaemia cells, and CaLu-1 human lung carcinoma cells were obtained from the American Type Culture Collection. Daoy human medulloblastoma cells were provided by Dr P. Jacobsen. All cell lines were grown in Dulbecco's modified Eagle's medium containing 10% foetal calf serum, penicillin (500ygml-1), streptomycin (50ygml-1) and neomycin (50 pgml-1) in an atmosphere containing CO2 (10%, v/v).
Antibodies
The preparation of antipeptide antibodies that recognise the met protein has been described previously (Tempest et al., 1986b) . Briefly, a peptide with the sequence VDTRPASFWETS that corresponds to the amino acid sequence at the C-terminal end of the predicted met gene product was synthesised. The peptide was coupled to keyhole limpet haemocyanin and the conjugate used to immunise rabbits. Antipeptide antibodies were purified by chromatography on an affinity column of immobilised synthetic peptide before use. The anti-EGF receptor antibody was purchased from Amersham International.
Immunoprecipitation and kinase assays Cells were washed in phosphate-buffered saline (PBS) and solubilized in 1 ml of lysis buffer (50 mM Tris HCl pH7.6, 150 mM NaCl, 100 mM benzamidine, 1% Nonidet-P40, 1 mM EGTA, 50 ,ig ml -1 phenylmethylsulphonyl fluoride, 10 jgml-l aprotinin and 5pgml-1 trypsin inhibitor).
Lysates were clarified by centrifugation at 12,000 g for 10min at 4°C. (Laemmli, 1970) . Samples that were analysed under nonreducing conditions were treated in a similar manner except that 2-mercaptoethanol was omitted. To detect phosphorylated proteins the gels were fixed in 10% acetic acid, dried and subject to autoradiography at -70°C for 0.5-6h using Fuji RX film. (Park et al., 1986a) . In agreement with the results of our previous study (Tempest et al., 1986b) (Park et al., 1987) revealed the interesting sequence Lys-Arg-Lys-Lys-Arg-Ser 303 amino acids from the amino terminus. This basic amino acid sequence is similar to the sequence Arg-Lys-Arg-Arg-Ser found at the cleavage site of the insulin receptor precursor (Ullrich et al., 1985) and to the sequence Arg-Lys-Arg-Arg-Asp found at the cleavage site of the precursor of the insulin-like growth factor I receptor (Ullrich et al., 1986) . A more detailed comparison of the basic amino acid sequence present in the human and mouse met proteins and those present in the precursor of the insulin and insulin-like growth factor I receptors is shown in Figure 4 . In the precursors of the insulin and insulin-like growth factor I receptors this is the p-subunit Arg-Lys-Arg-Arg -Ser
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The amino acid sequences at the proteolytic cleavage sites used for the processing of the precursors of the insulin receptor and insulin-like I growth factor receptor into a and ,B subunits are compared to amino acid sequences present in the predicted mouse and human met gene products. Amino acids 720-724 of the precursor of the insulin receptor (Ullrich et al., 1985) and amino acids 707-711 of the precursor of the insulin-like growth factor I receptor (Ullrich et al., 1986) (Park et al., 1987) . The amino terminal of the /3 subunits of the insulin receptor and insulin-like growth factor I receptor are indicated by the arrow.
site for cleavage of the precursor into the a and ,B subunits, which in the mature receptor are joined by disulphide bonds in an ocf2#2 configuration (for example see Ronnett et al., 1984) . Cleavage of the basic sequence present in the product of the human met gene would generate an N-terminal peptide of 283 amino acids that might become associated with the remaining membrane bound portion of the met proteins in a manner similar to that observed for the insulin and insulin-like growth factor I receptors. To test the possibility that the product of the met gene exists as a multisubunit complex we have subjected met protein that had been 32P-labelled in vitro by autophosphorylation to electrophoresis in denaturing SDS-polyacrylamide gels under either reducing or non-reducing conditions. When the proteins were analysed under conditions that should convert multisubunit proteins joined by disulphide bonds to their component subunits (reducing conditions) the usual 140kD met protein was observed ( Figure 5 ). However when the proteins were analysed under conditions that should not dissociate multisubunit proteins joined by disulphide bonds (non-reducing conditions) a 165 kD protein was detected ( Figure 5 ). When considered together these observations suggest that the mature met protein may exist as an a4 complex in which the 140 kD # subunit is joined to a smaller, 25 kD, a subunit, although the proposed a-subunit has not been detected directly in these experiments.
Discussion
In this study we In a previous study, analysis of the met proteins immunoprecipitated from HOS cells that had been metabolically labelled with 35S-methionine revealed that the pattern of expression of the met gene was complex (Park et al., 1986b) . Proteins with apparent molecular weights of 160 kD, 140 kD and 110 kD were detected but the relationship between these proteins was not determined. For example it was not known whether the smaller polypeptides are derived from the larger proteins by proteolytic cleavage or whether they represent completely independent products. The protein encoded by the human met gene possesses the amino acid sequence LysArg-Lys-Lys-Arg-Ser that is similar to the amino acid sequence found at the site of proteolytic cleavage site of the precursors at the insulin and insulin-like I growth factor receptors into a and f subunits (Ullrich et al., 1985 (Ullrich et al., , 1986 which in the mature receptors are joined by disulphide bonds in an a2f2 configuration. Allowing for increase in the size of the met protein that may result from post-translational glycosylation the predicted sizes of the met protein before and after cleavage at this position (respectively, 154kD and 122kD) are in reasonable agreement with the sizes of the two largest met proteins, pl6Omel and p140me'. Thus, it is possible that pm40me, is derived from pl60meI by proteolytic cleavage at this stretch of basic amino acids. Evidence that the met protein can exist as an a,B complex in which the two subunits are joined by disulphide bonds was obtained when met protein that had been 32P-labelled by autophosphorylation was subject to SDS-polyacrylamide gel electrophoresis under non-reducing conditions. The pl40net, which is the major protein 32P-labelled in these experiments, had an apparent size of 165 kD when run in a non-reducing gel, indicating that in the mature met protein the pl40?mt (designated the P subunit) may be associated with a smaller, 25 kD, a subunit. Although we have not detected the a subunit directly in these analyses, by analogy with the structure of the insulin and insulin-like I growth factor receptors we would expect the oe subunit to be derived from the N-terminal met polypeptide that is formed following proteolytic cleavage at amino acid sequence Lys-ArgLys-Lys-Agr-Ser. The proposed structure of the a/I met complex is shown in Figure 6 where its structure is compared with those of other classes of growth factor receptors that possess an intracellular protein tyrosine kinase domain.
In conclusion, we have demonstrated that considerable quantitative and qualitative variation in met kinase activity is found among human tumour cell lines and we have provided evidence that the met protein may exist as an ac/ complex in which the two subunits are joined by disulphide bonds. In future studies we hope to investigate the significance of this large variation in met kinase activity and to learn more about the structure of the mature met protein.
